Results 171 to 180 of about 32,698 (277)

Genomic and structural analysis of major antigenic proteins' variability in the human relapsing fever spirochete <i>Borrelia persica</i>. [PDF]

open access: yesCurr Res Microb Sci
Shwartz D   +6 more
europepmc   +1 more source

Historical overview and update on relapsing fever group Borrelia in Latin America. [PDF]

open access: yesParasit Vectors, 2022
Faccini-Martínez ÁA   +6 more
europepmc   +1 more source

Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis

open access: yesBritish Journal of Haematology, EarlyView.
Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui   +7 more
wiley   +1 more source

Tick borne relapsing fever - a systematic review and analysis of the literature. [PDF]

open access: yesPLoS Negl Trop Dis, 2022
Jakab Á   +3 more
europepmc   +1 more source

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial

open access: yesBJU International, Volume 135, Issue 4, Page 638-647, April 2025.
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui   +2 more
wiley   +1 more source

Genome report: whole-genome assembly of the relapsing fever tick Ornithodoros turicata Dugès (Acari: Argasidae). [PDF]

open access: yesG3 (Bethesda)
Tietjen M   +10 more
europepmc   +1 more source

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

open access: yesCancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy